Compare XLO & BNKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | BNKK |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 38.6M |
| IPO Year | 2021 | 2020 |
| Metric | XLO | BNKK |
|---|---|---|
| Price | $0.65 | $3.85 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 528.0K | ★ 771.9K |
| Earning Date | 11-13-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,804,000.00 | $2,293,124.00 |
| Revenue This Year | $589.60 | N/A |
| Revenue Next Year | $38.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | 251.44 |
| 52 Week Low | $0.62 | $3.05 |
| 52 Week High | $1.70 | $46.90 |
| Indicator | XLO | BNKK |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | N/A |
| Support Level | $0.68 | N/A |
| Resistance Level | $0.73 | N/A |
| Average True Range (ATR) | 0.04 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 10.24 | 0.00 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.